EMA-话题@MedSci

#EMA#

580篇内容 | 2476人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1317574, encodeId=9dbe131e57444, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Ann Hematol：中国原发性中枢神经系统淋巴瘤, objectType=article, longId=196536, objectId=3079196536e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3079196536e4, replyNumber=0, likeNumber=93, createdTime=2020-06-27, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3079196536e4, moduleTitle=Ann Hematol：中国原发性中枢神经系统淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3079196536e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317573, encodeId=171c131e57310, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Hematol Oncol：雌激素受体-α在1-2级和3级滤泡性淋巴瘤患者滤泡树状细胞上的差异性表达, objectType=article, longId=196148, objectId=6a1f19614846, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a1f19614846, replyNumber=0, likeNumber=117, createdTime=2020-06-21, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a1f19614846, moduleTitle=Hematol Oncol：雌激素受体-α在1-2级和3级滤泡性淋巴瘤患者滤泡树状细胞上的差异性表达, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a1f19614846)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317572, encodeId=9064131e57229, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=2020年EAN：AJOVY（fremanezumab）治疗难治性偏头痛安全有效, objectType=article, longId=194742, objectId=8ebd194e4268, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ebd194e4268, replyNumber=0, likeNumber=63, createdTime=2020-05-28, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ebd194e4268, moduleTitle=2020年EAN：AJOVY（fremanezumab）治疗难治性偏头痛安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ebd194e4268)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317571, encodeId=bf9a131e57120, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=EMA开始审查MorphoSys的CD19单抗tafasitamab，治疗淋巴瘤, objectType=article, longId=194616, objectId=2a611946163b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a611946163b, replyNumber=0, likeNumber=74, createdTime=2020-05-24, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a611946163b, moduleTitle=EMA开始审查MorphoSys的CD19单抗tafasitamab，治疗淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a611946163b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317570, encodeId=7c92131e5705c, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=诺和诺德的GLP-1激动剂索马鲁肽（Semaglutide）治疗肥胖症，III期临床试验成功, objectType=article, longId=194316, objectId=c1c619431626, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1c619431626, replyNumber=0, likeNumber=68, createdTime=2020-05-19, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1c619431626, moduleTitle=诺和诺德的GLP-1激动剂索马鲁肽（Semaglutide）治疗肥胖症，III期临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1c619431626)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317569, encodeId=4258131e569d7, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=诺和诺德的GLP-1激动剂semaglutide：非酒精性脂肪性肝炎的II期临床展现治疗潜力, objectType=article, longId=193810, objectId=97c7193810df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97c7193810df, replyNumber=0, likeNumber=70, createdTime=2020-05-10, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97c7193810df, moduleTitle=诺和诺德的GLP-1激动剂semaglutide：非酒精性脂肪性肝炎的II期临床展现治疗潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97c7193810df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317568, encodeId=c30a131e568c7, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=NEJM：Emapalumab治疗原发性噬血细胞性淋巴组织细胞增多症, objectType=article, longId=193715, objectId=511c193e15ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=511c193e15ce, replyNumber=0, likeNumber=78, createdTime=2020-05-09, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=511c193e15ce, moduleTitle=NEJM：Emapalumab治疗原发性噬血细胞性淋巴组织细胞增多症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=511c193e15ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317567, encodeId=1c48131e567cb, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet haematol：新型靶向药是否可取代自体造血干细胞移植？, objectType=article, longId=193394, objectId=5043193394ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5043193394ef, replyNumber=0, likeNumber=67, createdTime=2020-05-04, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5043193394ef, moduleTitle=Lancet haematol：新型靶向药是否可取代自体造血干细胞移植？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5043193394ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317566, encodeId=9fd5131e566a3, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet oncol：abemaciclib+曲妥珠单抗+氟维司群联合疗法可显著提高晚期HER2阳性乳腺癌患者的无进展存活期, objectType=article, longId=193392, objectId=a9c11933925d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9c11933925d, replyNumber=0, likeNumber=49, createdTime=2020-05-04, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9c11933925d, moduleTitle=Lancet oncol：abemaciclib+曲妥珠单抗+氟维司群联合疗法可显著提高晚期HER2阳性乳腺癌患者的无进展存活期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9c11933925d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317565, encodeId=2374131e5655b, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=欧盟EMA为T细胞疗法ADP-A2M4授予孤儿药指定，用于治疗软组织肉瘤, objectType=article, longId=193369, objectId=5b57193369b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b57193369b8, replyNumber=0, likeNumber=63, createdTime=2020-05-03, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b57193369b8, moduleTitle=欧盟EMA为T细胞疗法ADP-A2M4授予孤儿药指定，用于治疗软组织肉瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b57193369b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317564, encodeId=811a131e56474, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet Haematol：伊布替尼联合FCR用于初发年轻CLL患者的起始治疗：一项单臂、多中心、2期临床研究, objectType=article, longId=193097, objectId=69fe19309e48, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69fe19309e48, replyNumber=0, likeNumber=61, createdTime=2020-04-29, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69fe19309e48, moduleTitle=Lancet Haematol：伊布替尼联合FCR用于初发年轻CLL患者的起始治疗：一项单臂、多中心、2期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69fe19309e48)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317563, encodeId=2783131e56316, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Lancet haematol：3期试验：达雷木单抗皮下注射和静脉注射治疗复发性/难治性多发性骨髓瘤的效果和安全性对比, objectType=article, longId=192943, objectId=28a119294391, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28a119294391, replyNumber=0, likeNumber=82, createdTime=2020-04-26, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28a119294391, moduleTitle=Lancet haematol：3期试验：达雷木单抗皮下注射和静脉注射治疗复发性/难治性多发性骨髓瘤的效果和安全性对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28a119294391)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317562, encodeId=e94b131e56219, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=EMA确认治疗光化性角化病的Picato凝胶存在致癌风险, objectType=article, longId=192749, objectId=39c4192e4982, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39c4192e4982, replyNumber=0, likeNumber=89, createdTime=2020-04-24, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39c4192e4982, moduleTitle=EMA确认治疗光化性角化病的Picato凝胶存在致癌风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39c4192e4982)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317561, encodeId=2eac131e561fc, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=EMA接受抗部分性癫痫发作药物cenobamate的销售授权申请, objectType=article, longId=191490, objectId=c3f6191490db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3f6191490db, replyNumber=0, likeNumber=68, createdTime=2020-04-06, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3f6191490db, moduleTitle=EMA接受抗部分性癫痫发作药物cenobamate的销售授权申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3f6191490db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317560, encodeId=a7f5131e5607a, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=欧洲药品管理局（EMA）：允许“同情使用”瑞德西韦（remdesivir）治疗COVID-19, objectType=article, longId=191467, objectId=538b19146ee0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=538b19146ee0, replyNumber=0, likeNumber=49, createdTime=2020-04-06, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=538b19146ee0, moduleTitle=欧洲药品管理局（EMA）：允许“同情使用”瑞德西韦（remdesivir）治疗COVID-19, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=538b19146ee0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317559, encodeId=a2f2131e559c0, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=EMA建议新冠病毒COVID-19感染的高血压患者，继续服用血管紧张素转化酶抑制剂, objectType=article, longId=191243, objectId=8009191243cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8009191243cd, replyNumber=0, likeNumber=10, createdTime=2020-04-03, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8009191243cd, moduleTitle=EMA建议新冠病毒COVID-19感染的高血压患者，继续服用血管紧张素转化酶抑制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8009191243cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317558, encodeId=3a45131e55874, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=Blood：特发性多中心Castleman病的mTOR激活增强, objectType=article, longId=191226, objectId=820019122655, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=820019122655, replyNumber=0, likeNumber=69, createdTime=2020-04-03, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=820019122655, moduleTitle=Blood：特发性多中心Castleman病的mTOR激活增强, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=820019122655)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317557, encodeId=7a32131e557ba, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=新冠疫情下临床试验指南--FDA, EMA和NMPA之比较, objectType=article, longId=191030, objectId=38b419103057, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=38b419103057, replyNumber=0, likeNumber=72, createdTime=2020-03-30, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=38b419103057, moduleTitle=新冠疫情下临床试验指南--FDA, EMA和NMPA之比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=38b419103057)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317556, encodeId=56f5131e5562d, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=FDA和EMA合作，促进COVID-19疫苗开发, objectType=article, longId=190832, objectId=095219083273, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=095219083273, replyNumber=0, likeNumber=61, createdTime=2020-03-27, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=095219083273, moduleTitle=FDA和EMA合作，促进COVID-19疫苗开发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=095219083273)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1317555, encodeId=2a4f131e55593, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, objectTitle=口腔颌面颈部Castleman病：6例临床病例报告和文献复习, objectType=article, longId=190292, objectId=aa5a19029234, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa5a19029234, replyNumber=0, likeNumber=52, createdTime=2020-03-20, rootId=0, userName=fengyi812, userId=a35a460, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa5a19029234, moduleTitle=口腔颌面颈部Castleman病：6例临床病例报告和文献复习, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa5a19029234)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

EMA

2020-05-29

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Ann Hematol：中国原发性中枢神经系统淋巴瘤

2020-06-27

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Hematol Oncol：雌激素受体-α在1-2级和3级滤泡性淋巴瘤患者滤泡树状细胞上的差异性表达

2020-06-21

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

2020年EAN：AJOVY（fremanezumab）治疗难治性偏头痛安全有效

2020-05-28

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

EMA开始审查MorphoSys的CD19单抗tafasitamab，治疗淋巴瘤

2020-05-24

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

诺和诺德的GLP-1激动剂索马鲁肽（Semaglutide）治疗肥胖症，III期临床试验成功

2020-05-19

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

诺和诺德的GLP-1激动剂semaglutide：非酒精性脂肪性肝炎的II期临床展现治疗潜力

2020-05-10

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

NEJM：Emapalumab治疗原发性噬血细胞性淋巴组织细胞增多症

2020-05-09

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet haematol：新型靶向药是否可取代自体造血干细胞移植？

2020-05-04

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet oncol：abemaciclib+曲妥珠单抗+氟维司群联合疗法可显著提高晚期HER2阳性乳腺癌患者的无进展存活期

2020-05-04

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

欧盟EMA为T细胞疗法ADP-A2M4授予孤儿药指定，用于治疗软组织肉瘤

2020-05-03

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet Haematol：伊布替尼联合FCR用于初发年轻CLL患者的起始治疗：一项单臂、多中心、2期临床研究

2020-04-29

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Lancet haematol：3期试验：达雷木单抗皮下注射和静脉注射治疗复发性/难治性多发性骨髓瘤的效果和安全性对比

2020-04-26

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

EMA确认治疗光化性角化病的Picato凝胶存在致癌风险

2020-04-24

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

EMA接受抗部分性癫痫发作药物cenobamate的销售授权申请

2020-04-06

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

欧洲药品管理局（EMA）：允许“同情使用”瑞德西韦（remdesivir）治疗COVID-19

2020-04-06

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

EMA建议新冠病毒COVID-19感染的高血压患者，继续服用血管紧张素转化酶抑制剂

2020-04-03

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

Blood：特发性多中心Castleman病的mTOR激活增强

2020-04-03

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

新冠疫情下临床试验指南--FDA, EMA和NMPA之比较

2020-03-30

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

FDA和EMA合作，促进COVID-19疫苗开发

2020-03-27

fengyi812 (审核中...)

前往app查看评论内容

#EMA#

口腔颌面颈部Castleman病：6例临床病例报告和文献复习

2020-03-20

科室
- - 订阅+
  - 更多科室
工具
服务